Fulcrum Therapeutics® to Present at the 40th Annual J.P. Morgan Healthcare Conference
Fulcrum Therapeutics (Nasdaq: FULC) announced that Bryan Stuart, President and CEO, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 p.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Fulcrum's website, with an archived replay accessible for 30 days following the event.
Fulcrum focuses on addressing rare diseases through innovative treatments like losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease, leveraging its proprietary product engine, FulcrumSeek™.
- None.
- None.
CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Bryan Stuart, President and Chief Executive Officer, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 12:00 p.m. ET.
A live audio webcast will be available through the Investor Relations section of the Fulcrum website at www.fulcrumtx.com. An archived replay will be available on Fulcrum’s website for 30 days.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.
Please visit www.fulcrumtx.com.
Contact:
Investors:
Christi Waarich
Director, Investor Relations and
Corporate Communications
cwaarich@fulcrumtx.com
617-651-8664
FAQ
What date will Fulcrum Therapeutics present at the J.P. Morgan Healthcare Conference?
What time will the presentation by Fulcrum Therapeutics take place?
How can I access the Fulcrum Therapeutics presentation?
Will there be a replay of the Fulcrum Therapeutics presentation?
What are the main clinical programs of Fulcrum Therapeutics?
